Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Conference call Celyad first half 2017

Conference call Celyad first half 2017

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

ASCO 2017 - A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

ASCO 2017 - A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types